LGALS9 and type 1 diabetes mellitus: Furthermore, the in vivo administration of PD-L1–Gal-9 aEVs resulted in a reduction in T cell infiltration in the pancreas, an increase in β-cell integrity protection, a significant decrease in blood glucose levels, and a delay in the progression of T1D.